Resolution via Diastereomeric Salt Crystallization of Ibuprofen Lysine: Ternary Phase Diagram Studies-Reference-Cited by-同舟云学术

Resolution via Diastereomeric Salt Crystallization of Ibuprofen Lysine: Ternary Phase Diagram Studies

Published:2018-03-25 Issue:5 Volume:41 Page:921-927
ISSN:0930-7516
Container-title:Chemical Engineering & Technology
language:en
Short-container-title:Chem. Eng. Technol.

Author:

Simon Melba¹,Donnellan Philip¹,Glennon Brian¹,Jones Roderick C.¹

Affiliation:

1. University College Dublin; School of Chemical and BioProcess Engineering, Synthesis and Solid State Pharmaceutical Centre (SSPC); Belfield Dublin 4 Ireland

Funder

Science Foundation Ireland

European Regional Development Fund

Publisher

Wiley

Subject

Industrial and Manufacturing Engineering,General Chemical Engineering,General Chemistry

Reference31 articles.

1. Design and development of chiral reagents for the chromatographic e.e. determination of chiral alcohols

2. Enantioenrichment by Crystallization

3. Drug chirality: a consideration of the significance of the stereochemistry of antimicrobial agents

4. Chiral separations

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Same but Not the Same: The Case of (S)-Naproxen/cis-1-Amino-2-indanol Chiral Resolution via Diastereomeric Salt Formation;Crystal Growth & Design;2024-02-05

2. Recycling of resolving agent and solvent by water-based reactions and phase diagrams: Chiral resolution study of racemic ibuprofen;Chemical Engineering Research and Design;2023-04

3. Green and efficient enantioseparation of amlodipine using a novel pairwise crystallization-circulating extraction coupling method aimed at in situ reuse of mother liquor;Separation and Purification Technology;2022-10

4. Recognition in the Domain of Molecular Chirality: From Noncovalent Interactions to Separation of Enantiomers;Chemical Reviews;2022-08-02

5. Design and Optimization of the Single-Stage Continuous Mixed Suspension–Mixed Product Removal Crystallization of 2-Chloro-N-(4-methylphenyl)propenamide;ACS Omega;2022-04-13